logo

Spasticity Treatment Market Size (2024 - 2029)

The spasticity treatment market is projected to experience significant growth over the forecast period, driven by an increase in the prevalence of conditions such as multiple sclerosis, cerebral palsy, and encephalitis. This growth is attributed to the rising demand for effective treatments, particularly for cerebral palsy, which is a leading cause of spasticity. The market's expansion is influenced by the growing need to address these neurological disorders across various geographical regions.

INSTANT ACCESS

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Developmental Anomalities Research Spasticity Treatment Market Market Size

Market Size of Spasticity Treatment Industry

Spasticity Treatment Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 1.31 Billion
Market Size (2029) USD 2.11 Billion
CAGR (2024 - 2029) 8.02 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Spasticity Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Spasticity Treatment Market Analysis

The Spasticity Treatment Market size is estimated at USD 1.31 billion in 2024, and is expected to reach USD 2.11 billion by 2029, growing at a CAGR of 8.02% during the forecast period (2024-2029).

The major factors attributing to the market's growth are a growing prevalence of multiple sclerosis, cerebral palsy, and encephalitis around the globe, a rise in awareness programs, and the adoption of novel technologies.

The rising cases of spasticity and the adoption of new technologies for spasticity treatment are the key drivers for the market. For instance, according to the journal published by the Physicians Group LLC in December 2023, around 12.0 million people worldwide suffer from spasticity. The same source also stated that contemporary physical therapy approaches, including robotic-assisted therapy, electrical stimulation therapies, and virtual reality therapy, showcased high efficiency in enhancing motor function and reducing spasticity in patients. Also, according to the study published in February 2023, robotic-assisted sensorimotor therapy exercises were applied on stroke subjects with severe spasticity and have showcased significant achievement. The study also stated that active therapy with rehabilitation devices can lead to various benefits in spasticity treatment.

Rising approvals and the launching specialty products to treat spasticity are anticipated to drive market growth. For instance, in June 2022, LYVISPAH, a baclofen oral granules (5, 10, and 20 mg) specialty product approved by the United States FDA for the treatment of spasticity related to multiple sclerosis and other spinal cord disorders, was commercially launched. Amneal Pharmaceutical has developed the product in the form of rapidly dissolving flavored granules to provide an alternative for spasticity patients who have difficulty swallowing pills.

Also, the rising research and development on advanced therapeutics for treating spasticity is anticipated to drive market growth further. For instance, in March 2023, Saol Therapeutics shared its Phase II results of the clinical development of SL-1002 for lower limb muscle spasticity. The phase transition success rate (PTSR) indication standard for Phase II medicines for Lower Limb Muscle Spasticity was found to be 100%. In addition, a pipeline drug, STI-103, is under clinical development by Sentynl Therapeutics and is currently in Phase I. The Phase I drug for muscle spasticity has a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Therefore, the positive results of spasticity drugs are expected to have the launch of advanced therapeutics for spasticity in the market, thereby anticipated to drive the market growth during the forecast period.

However, the high cost of the treatment is expected to reduce the adoption rate of spasticity treatment, which is expected to hinder the market growth during the forecast period.

Spasticity Treatment Industry Segmentation

Spasticity is a physiological condition in which the contraction of muscles occurs continuously, leading to tightening of muscles and prolonged stiffness. The spasticity may occur due to various disorders such as multiple sclerosis, meningitis, and other conditions such as injury to the spinal cord and others. The spasticity drugs market is segmented by drug class, indication, route of administration, end user, and geography. By drug class, the market segment includes GABA agonists, alpha2-adrenergic agonists, botulinum toxins, and other drug classes. By indication, the market segment includes multiple sclerosis, cerebral palsy, traumatic brain injury, and other indications. By route of administration, the market segment includes oral and parental. By end user, the market segment includes pediatrics and adults. By geography, the market segment includes North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers market size and forecasts for all the above segments in value (USD).

Drug Class
GABA Agonist
Alpha2-adrenergic Agonists
Botulinum Toxins
Other Drug Class
Indication
Multiple Sclerosis (MS)
Cerebral Palsy (CP)
Traumatic Brain Injury (TBI)
Other Indications
Route of Administration
Oral
Parenteral
End User
Pediatrics
Adults
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Spasticity Treatment Market Size Summary

The spasticity treatment market is poised for significant growth, driven by the increasing prevalence of conditions such as multiple sclerosis, cerebral palsy, and encephalitis. These conditions have led to a rising demand for effective treatments, with cerebral palsy being a major contributor to spasticity cases globally. The market is characterized by the dominance of the oral route segment, which is favored for its ease of administration and the growing demand for combination products. North America is expected to lead the market, supported by a high incidence of traumatic brain injuries and a growing elderly population. The region benefits from advanced healthcare infrastructure and initiatives to raise health awareness, further propelling market growth.

The competitive landscape of the spasticity treatment market features several key players actively developing new products to meet unmet medical needs. Companies like Medtronic Plc, Piramal Enterprises Ltd, Allergan plc, Ipsen, and F. Hoffmann-La Roche Ltd are at the forefront, with recent product approvals enhancing their market positions. The approval of Dysport in the UK and the expanded use of XEOMIN in the United States highlight the ongoing innovation and regulatory support in the industry. These developments, coupled with the strategic initiatives by major players, are expected to drive the market's expansion over the forecast period.

Explore More

Spasticity Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rise in Awareness Programs and Adoption of Novel Technologies

      2. 1.2.2 Launch of Advanced Therapeutics and Increased Affordability

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of Treatment

      2. 1.3.2 Stringent Regulatory Framework

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drug Class

      1. 2.1.1 GABA Agonist

      2. 2.1.2 Alpha2-adrenergic Agonists

      3. 2.1.3 Botulinum Toxins

      4. 2.1.4 Other Drug Class

    2. 2.2 Indication

      1. 2.2.1 Multiple Sclerosis (MS)

      2. 2.2.2 Cerebral Palsy (CP)

      3. 2.2.3 Traumatic Brain Injury (TBI)

      4. 2.2.4 Other Indications

    3. 2.3 Route of Administration

      1. 2.3.1 Oral

      2. 2.3.2 Parenteral

    4. 2.4 End User

      1. 2.4.1 Pediatrics

      2. 2.4.2 Adults

    5. 2.5 Geography

      1. 2.5.1 North America

        1. 2.5.1.1 United States

        2. 2.5.1.2 Canada

        3. 2.5.1.3 Mexico

      2. 2.5.2 Europe

        1. 2.5.2.1 Germany

        2. 2.5.2.2 United Kingdom

        3. 2.5.2.3 France

        4. 2.5.2.4 Italy

        5. 2.5.2.5 Spain

        6. 2.5.2.6 Rest of Europe

      3. 2.5.3 Asia-Pacific

        1. 2.5.3.1 China

        2. 2.5.3.2 Japan

        3. 2.5.3.3 India

        4. 2.5.3.4 Australia

        5. 2.5.3.5 South Korea

        6. 2.5.3.6 Rest of Asia-Pacific

      4. 2.5.4 Middle East and Africa

        1. 2.5.4.1 GCC

        2. 2.5.4.2 South Africa

        3. 2.5.4.3 Rest of Middle East and Africa

      5. 2.5.5 South America

        1. 2.5.5.1 Brazil

        2. 2.5.5.2 Argentina

        3. 2.5.5.3 Rest of South America

Spasticity Treatment Market Size FAQs

The Spasticity Treatment Market size is expected to reach USD 1.31 billion in 2024 and grow at a CAGR of 8.02% to reach USD 2.11 billion by 2029.

In 2024, the Spasticity Treatment Market size is expected to reach USD 1.31 billion.

Spasticity Treatment Market Report Snapshots

Spasticity Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)